234 related articles for article (PubMed ID: 33216881)
21. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
22. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
Crea F
Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
[No Abstract] [Full Text] [Related]
23. Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors.
Carbone S; Dixon DL; Abbate A
JACC Heart Fail; 2018 Jan; 6(1):85. PubMed ID: 29284585
[No Abstract] [Full Text] [Related]
24. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.
Docherty KF; McMurray JJV
Eur J Heart Fail; 2021 Jan; 23(1):27-30. PubMed ID: 33283384
[No Abstract] [Full Text] [Related]
25. A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?
Mishriky BM; Cummings DM; Powell JR
Diabetes Metab Res Rev; 2024 Jan; 40(1):e3715. PubMed ID: 37649368
[No Abstract] [Full Text] [Related]
26. Another brick in the wall of cardioprotection? A meta-analysis addressing the effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass assessed by cardiovascular magnetic resonance in patients with heart failure with reduced ejection fraction.
Patoulias D; Boulmpou A; Doumas M; Papadopoulos CE
J Cardiovasc Med (Hagerstown); 2022 Aug; 23(8):570-572. PubMed ID: 35905005
[No Abstract] [Full Text] [Related]
27. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.
Zaina A; Prencipe N; Golden E; Berton AM; Arad E; Abid A; Shehadeh J; Kassem S; Ghigo E
Endocrine; 2023 Jun; 80(3):491-499. PubMed ID: 37000406
[No Abstract] [Full Text] [Related]
28. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
Liang B; Gu N
Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
[TBL] [Abstract][Full Text] [Related]
29. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
Butler J; Zannad F; Filippatos G; Anker SD; Packer M
Eur Heart J; 2020 Sep; 41(36):3398-3401. PubMed ID: 32935133
[No Abstract] [Full Text] [Related]
30. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?
Khouri MG; Greene SJ
JACC Heart Fail; 2022 Aug; 10(8):568-570. PubMed ID: 35902160
[No Abstract] [Full Text] [Related]
31. Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study.
Patoulias D; Toumpourleka M; Katsimardou A; Zografou I; Stavropoulos K; Imprialos K; Karagiannis A; Doumas M; Papadopoulos C
Kardiol Pol; 2022; 80(6):696-698. PubMed ID: 35445742
[No Abstract] [Full Text] [Related]
32. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure.
Farmakis D; Butler J; Filippatos G
Eur J Heart Fail; 2020 Jul; 22(7):1259-1262. PubMed ID: 32533724
[No Abstract] [Full Text] [Related]
33. Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.
Varughese GI; Jacob S
J R Soc Med; 2023 Dec; 116(12):408. PubMed ID: 38054392
[No Abstract] [Full Text] [Related]
34. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021).
Dashora U; Gregory R; Winocour P; Dhatariya K; Rowles S; Macklin A; Rayman G; Nagi D; Whitehead K; Beba H; De P; Patel DC;
Clin Med (Lond); 2021 May; 21(3):204-210. PubMed ID: 34001571
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure.
Patoulias D; Papadopoulos C; Doumas M
J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683
[No Abstract] [Full Text] [Related]
36. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
37. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
Butler J; Anker SD
Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
[No Abstract] [Full Text] [Related]
38. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest.
Patoulias D; Papadopoulos C; Katsimardou A; Doumas M
Am J Cardiol; 2021 Jan; 139():134-136. PubMed ID: 33075281
[No Abstract] [Full Text] [Related]
39. Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
Groenewegen A; Rutten FH
Eur J Heart Fail; 2020 Apr; 22(4):723-725. PubMed ID: 32072715
[No Abstract] [Full Text] [Related]
40. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta
Joshi SS; Singh T; Singh J; Newby DE
Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
